Klotho Neurosciences (NASDAQ:KLTO) Posts Quarterly Earnings Results

Klotho Neurosciences (NASDAQ:KLTO) released its earnings results on Monday. The company reported ($0.12) EPS for the quarter, Zacks reports.

Klotho Neurosciences Trading Up 10.4%

KLTO stock opened at $0.86 on Monday. The firm has a market cap of $39.61 million, a P/E ratio of -2.39 and a beta of 10.90. Klotho Neurosciences has a 12-month low of $0.11 and a 12-month high of $3.91. The stock’s 50 day simple moving average is $1.23 and its 200 day simple moving average is $0.59.

Institutional Investors Weigh In On Klotho Neurosciences

An institutional investor recently bought a new position in Klotho Neurosciences stock. Jane Street Group LLC purchased a new stake in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences at the end of the most recent quarter. Hedge funds and other institutional investors own 20.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Klotho Neurosciences to a “sell” rating in a research report on Saturday, July 5th.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.